Literature DB >> 19121808

Antiarrhythmic effect of IKr activation in a cellular model of LQT3.

Jonas Goldin Diness1, Rie Schultz Hansen, Jakob Dahl Nissen, Thomas Jespersen, Morten Grunnet.   

Abstract

BACKGROUND: Long QT syndrome type 3 (LQT3) is an inherited cardiac disorder caused by gain-of-function mutations in the cardiac voltage-gated sodium channel, Na(v)1.5. LQT3 is associated with the polymorphic ventricular tachycardia torsades de pointes (TdP), which can lead to syncope and sudden cardiac death. The sea anemone toxin ATX-II has been shown to inhibit the inactivation of Na(v)1.5, thereby closely mimicking the underlying cause of LQT3 in patients.
OBJECTIVE: The hypothesis for this study was that activation of the I(Kr) current could counteract the proarrhythmic effects of ATX-II.
METHODS: Two different activators of I(Kr), NS3623 and mallotoxin (MTX), were used in patch clamp studies of ventricular cardiac myocytes acutely isolated from guinea pig to test the effects of selective I(Kr) activation alone and in the presence of ATX-II. Action potentials were elicited at 1 Hz by current injection and the cells were kept at 32 degrees C to 35 degrees C.
RESULTS: NS3623 significantly shortened action potential duration at 90% repolarization (APD(90)) compared with controls in a dose-dependent manner. Furthermore, it reduced triangulation, which is potentially antiarrhythmic. Application of ATX-II (10 nM) was proarrhythmic, causing a profound increase of APD(90) as well as early afterdepolarizations and increased beat-to-beat variability. Two independent I(Kr) activators attenuated the proarrhythmic effects of ATX-II. NS3623 did not affect the late sodium current (I(NaL)) in the presence of ATX-II. Thus, the antiarrhythmic effect of NS3623 is likely to be caused by selective I(Kr) activation.
CONCLUSION: The present data show the antiarrhythmic potential of selective I(Kr) activation in a cellular model of the LQT3 syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19121808     DOI: 10.1016/j.hrthm.2008.10.020

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  6 in total

1.  Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.

Authors:  Morten Grunnet; Jennifer Abbruzzese; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2010-09-27       Impact factor: 4.436

2.  Re-evaluating the efficacy of beta-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling.

Authors:  Rebecca C Ahrens-Nicklas; Colleen E Clancy; David J Christini
Journal:  Cardiovasc Res       Date:  2009-03-05       Impact factor: 10.787

3.  In silico assessment of drug safety in human heart applied to late sodium current blockers.

Authors:  Beatriz Trenor; Julio Gomis-Tena; Karen Cardona; Lucia Romero; Sridharan Rajamani; Luiz Belardinelli; Wayne R Giles; Javier Saiz
Journal:  Channels (Austin)       Date:  2013 Jul-Aug       Impact factor: 2.581

4.  Restoring repolarization in LQT3.

Authors:  Alfred L George
Journal:  Heart Rhythm       Date:  2008-10-29       Impact factor: 6.343

Review 5.  Disease Modifiers of Inherited SCN5A Channelopathy.

Authors:  Arie O Verkerk; Ahmad S Amin; Carol Ann Remme
Journal:  Front Cardiovasc Med       Date:  2018-10-01

Review 6.  Arrhythmogenic Remodeling in the Failing Heart.

Authors:  Zoltán Husti; András Varró; István Baczkó
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.